Ohbayashi Hiroyuki, Miyazawa Chihiro, Miyamoto Kyoko, Sagara Mina, Yamashita Tetsuji, Onda Ryouichi
Department of Internal Medicine, JA Gifu Tohno-Kousei Hospital, Gifu, Japan.
J Atheroscler Thromb. 2009 Aug;16(4):490-500. doi: 10.5551/jat.no613. Epub 2009 Sep 3.
To investigate the effect of pitavastatin on asymptomatic atherosclerosis in patients with hypercholesterolemia.
Thirty-five outpatients with hypercholesterolemia (61.5+/-12.8 yr) were administered 2 mg oral pitavastatin daily for 6 months. Plasma pentraxin 3 (PTX3), a novel inflammatory marker of atherosclerosis, was measured together with the serum hsCRP and carotid-artery intima-media thickness (IMT).
Significant improvement of the LDL-C/HDL-C and log (TG/HDL-C) ratios began to be observed from 1 month after using pitavastatin. Significant correlation of the initial PTX3 value was observed with the initial plaque score (PS) (p=0.038, r=0.246), but not between the hsCRP and plasma PTX3 or PS. When patients were divided into 3 groups based on the initial PTX3 values, a significant decrease of the plasma PTX3 was obtained in the highest PTX3 group alone (p=0.034). The change in the plasma PTX3 value (DeltaPTX3) was significantly correlated with the Delta mean IMT during the study period (p=0.008, r=0.456).
Pitavastatin significantly reduced the elevated plasma levels of PTX3 in patients with hypercholesterolemia by its pleiotropic effect against atherosclerotic inflammation. This study showed for the first time that the plasma PTX3 might be a useful blood parameter for direct detection of active atherosclerotic change.
探讨匹伐他汀对高胆固醇血症患者无症状动脉粥样硬化的影响。
35例高胆固醇血症门诊患者（61.5±12.8岁），每日口服2mg匹伐他汀，共6个月。检测血浆五聚体3（PTX3），一种新型动脉粥样硬化炎症标志物，同时检测血清高敏C反应蛋白（hsCRP）和颈动脉内膜中层厚度（IMT）。
使用匹伐他汀1个月后，LDL-C/HDL-C和log（TG/HDL-C）比值开始有显著改善。初始PTX3值与初始斑块评分（PS）有显著相关性（p=0.038，r=0.246），但hsCRP与血浆PTX3或PS之间无相关性。根据初始PTX3值将患者分为3组，仅最高PTX3组血浆PTX3有显著下降（p=0.034）。研究期间血浆PTX3值变化（ΔPTX3）与Δ平均IMT显著相关（p=0.008，r=0.456）。
匹伐他汀通过其对动脉粥样硬化炎症的多效性作用，显著降低高胆固醇血症患者升高的血浆PTX3水平。本研究首次表明，血浆PTX3可能是直接检测活动性动脉粥样硬化改变的有用血液参数。
